This Outlook article stated that Addex Pharmaceuticals has mGluR5 modulators in phase II trials for anxiety and depression. The company says that its only disclosed mGluR5 inhibitor in development, ADX48621, will soon enter phase II testing for Parkinson’s disease levodopa-induced dyskinesia and non-Parkinson’s dystonia.
Additional information
The online version of the original article can be found at 10.1038/466S15a
Rights and permissions
About this article
Cite this article
Smith, K. Erratum: Treatment frontiers. Nature 467, 622 (2010). https://doi.org/10.1038/nature09476
Issue Date:
DOI: https://doi.org/10.1038/nature09476
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
